Aoibhinn McDonnell

648 total citations
19 papers, 294 citations indexed

About

Aoibhinn McDonnell is a scholar working on Genetics, Surgery and Hepatology. According to data from OpenAlex, Aoibhinn McDonnell has authored 19 papers receiving a total of 294 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Genetics, 6 papers in Surgery and 6 papers in Hepatology. Recurrent topics in Aoibhinn McDonnell's work include Inflammatory Bowel Disease (12 papers), Liver Diseases and Immunity (6 papers) and Microscopic Colitis (5 papers). Aoibhinn McDonnell is often cited by papers focused on Inflammatory Bowel Disease (12 papers), Liver Diseases and Immunity (6 papers) and Microscopic Colitis (5 papers). Aoibhinn McDonnell collaborates with scholars based in United Kingdom, United States and Belgium. Aoibhinn McDonnell's co-authors include Zahid Ali, Richard P. Butt, Susie M. Collins, Laura Iavarone, Simon Kirby, Sulayman D. Dib‐Hajj, Tina Mainka, Sanela Tarabar, Stephen G. Waxman and Betsy R. Schulman and has published in prestigious journals such as Gastroenterology, Brain and Pain.

In The Last Decade

Aoibhinn McDonnell

13 papers receiving 280 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aoibhinn McDonnell United Kingdom	7	147	132	74	73	56	19	294
Costanza Varesio Italy	11	142 1.0×	103 0.8×	43 0.6×	87 1.2×	55 1.0×	40	402
Jason Lockrow United States	8	107 0.7×	99 0.8×	33 0.4×	95 1.3×	39 0.7×	13	368
Ana Rita Castro Portugal	9	111 0.8×	62 0.5×	75 1.0×	21 0.3×	18 0.3×	18	260
Miren Altuna Spain	11	112 0.8×	136 1.0×	35 0.5×	54 0.7×	24 0.4×	26	363
Dana Button United States	9	46 0.3×	120 0.9×	54 0.7×	79 1.1×	18 0.3×	14	318
Aleksandra Kaliszewska United Kingdom	8	105 0.7×	157 1.2×	43 0.6×	23 0.3×	27 0.5×	9	297
Kana Meece United States	12	91 0.6×	136 1.0×	53 0.7×	40 0.5×	18 0.3×	12	401
Elizabeth Ensink United States	6	91 0.6×	174 1.3×	41 0.6×	30 0.4×	53 0.9×	7	380
Ahmed Abdelmoity United States	11	52 0.4×	55 0.4×	33 0.4×	95 1.3×	42 0.8×	25	264
Nadine M. Aziz United States	7	58 0.4×	95 0.7×	35 0.5×	97 1.3×	25 0.4×	7	301

Countries citing papers authored by Aoibhinn McDonnell

Since Specialization

Citations

This map shows the geographic impact of Aoibhinn McDonnell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aoibhinn McDonnell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aoibhinn McDonnell more than expected).

Fields of papers citing papers by Aoibhinn McDonnell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aoibhinn McDonnell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aoibhinn McDonnell. The network helps show where Aoibhinn McDonnell may publish in the future.

Co-authorship network of co-authors of Aoibhinn McDonnell

This figure shows the co-authorship network connecting the top 25 collaborators of Aoibhinn McDonnell. A scholar is included among the top collaborators of Aoibhinn McDonnell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aoibhinn McDonnell. Aoibhinn McDonnell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Vermeire, Séverine, David T. Rubin, Laurent Peyrin-Biroulet, et al.. (2025). Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis. BMJ Open Gastroenterology. 12(1). e001516–e001516. 6 indexed citations

Sands, Bruce E., Marla C. Dubinsky, Paulo Gustavo Kotze, et al.. (2025). Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program. Inflammatory Bowel Diseases. 31(10). 2681–2692.

Takeuchi, Ken, Hiroshi Nakase, Katsuyoshi Matsuoka, et al.. (2025). Efficacy and safety of etrasimod in Japanese patients with ulcerative colitis: results from a phase 2 dose-ranging study. Intestinal Research.

Lichtenstein, Gary R., Jessica R. Allegretti, Edward V. Loftus, et al.. (2025). Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program. Inflammatory Bowel Diseases. 31(9). 2352–2362. 1 indexed citations

Peyrin‐Biroulet, Laurent, Marla C. Dubinsky, Bruce E. Sands, et al.. (2024). Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme. Journal of Crohn s and Colitis. 18(8). 1270–1282. 16 indexed citations

Regueiro, Miguel, Britta Siegmund, Andrés Yarur, et al.. (2024). Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical Programme. Journal of Crohn s and Colitis. 18(10). 1596–1605. 6 indexed citations

Lees, Charlie W., Joana Torres, Yvette Leung, et al.. (2024). Non-serious adverse events in patients with ulcerative colitis receiving etrasimod: an analysis of the phase II OASIS and phase III ELEVATE UC 52 and ELEVATE UC 12 clinical trials. Therapeutic Advances in Gastroenterology. 17. 1118476619–1118476619. 1 indexed citations

Yarur, Andrés, Michael Chiorean, Jessica R. Allegretti, et al.. (2024). Etrasimod as a Monotherapy or With Concomitant Use of Corticosteroids and/or Aminosalicylates: Results From the ELEVATE UC Clinical Program. Inflammatory Bowel Diseases. 31(8). 2144–2153.

Dubinsky, Marla C., Joseph Wu, Aoibhinn McDonnell, et al.. (2024). S1084 Low Incidence of Macular Edema in Patients in the Etrasimod Clinical Program. The American Journal of Gastroenterology. 119(10S). S768–S769.

10.

D’Haens, Geert, Marla C. Dubinsky, Laurent Peyrin-Biroulet, et al.. (2024). S1083 Etrasimod for Moderately to Severely Active Crohn’s Disease: Results From the Extension Period of a Phase 2 Study. The American Journal of Gastroenterology. 119(10S). S767–S768.

11.

Gecse, K, María Chaparro, María T. Abreu, et al.. (2024). S1437 Pregnancy Outcomes in the Etrasimod Clinical Program. The American Journal of Gastroenterology. 119(10S). S1032–S1032. 5 indexed citations

12.

Dubinsky, Marla C., Joseph Wu, Aoibhinn McDonnell, et al.. (2024). Low Incidence of Macular Edema and Other Ocular Events in the Etrasimod Development Program. Journal of Crohn s and Colitis. 19(5). 2 indexed citations

13.

Regueiro, Miguel, Séverine Vermeire, David T. Rubin, et al.. (2023). S1072 Hepatic Impact of Etrasimod for Treatment of Moderately to Severely Active Ulcerative Colitis: An Integrated Safety Summary From the Etrasimod Ulcerative Colitis Clinical Program. The American Journal of Gastroenterology. 118(10S). S816–S817. 1 indexed citations

14.

Vermeire, Séverine, David T. Rubin, Laurent Peyrin‐Biroulet, et al.. (2023). S905 Impact of Etrasimod on Blood Pressure and Hypertension: Data From the Etrasimod Ulcerative Colitis Clinical Program. The American Journal of Gastroenterology. 118(10S). S675–S675.

15.

Vermeire, Séverine, Laurent Peyrin‐Biroulet, Julián Panés, et al.. (2023). 948 ETRASIMOD FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 2.5 YEARS OF POOLED SAFETY DATA FROM GLOBAL CLINICAL TRIALS. Gastroenterology. 164(6). S–207. 2 indexed citations

16.

Siebenga, Pieter, Guido van Amerongen, Justin L. Hay, et al.. (2019). Lack of Detection of the Analgesic Properties of PF‐05089771, a Selective Na_v1.7 Inhibitor, Using a Battery of Pain Models in Healthy Subjects. Clinical and Translational Science. 13(2). 318–324. 36 indexed citations

17.

McDonnell, Aoibhinn, Susie M. Collins, Zahid Ali, et al.. (2018). Efficacy of the Nav1.7 blocker PF-05089771 in a randomised, placebo-controlled, double-blind clinical study in subjects with painful diabetic peripheral neuropathy. Pain. 159(8). 1465–1476. 111 indexed citations

18.

McDonnell, Aoibhinn, Betsy R. Schulman, Zahid Ali, et al.. (2016). Inherited erythromelalgia due to mutations inSCN9A:natural history, clinical phenotype and somatosensory profile. Brain. 139(4). 1052–1065. 59 indexed citations

19.

Charman, Tony, Hayley Archer, Mary Gardiner, et al.. (2005). Dimensional phenotypic analysis and functional categorisation of mutations reveal novel genotype–phenotype associations in Rett syndrome. European Journal of Human Genetics. 13(10). 1121–1130. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact